Prognostic value and anti-tumor immunity role of TMED9 in pan-cancer: a bioinformatics study
Abstract Background: Transmembrane p24 trafficking protein 9 (TMED9) belongs to the TMED family, and its overexpression frequently induces cancer. Studies have demonstrated the association between the overexpression of TMED9 and cancer development and proliferative migration in cancers such as ovarian cancer, hepatocellular carcinoma, and breast cancer. However, there has been no study investigating the clinical value, biological function, and anti-tumor immune effects of TMED9 from a pan-cancer perspective. The aim of this study is to evaluate the prognostic value and
This article is available to registered members
Create a free account to access our full library of peer-reviewed research on medical cannabis.
Join — it's freeAlready a member? Log in
